Community transmission and viral load kinetics of the sin vaccinated and unvaccinated individuals in the UK: a study

Lancet Infectious Diseases, The 22, 183-195

DOI: 10.1016/s1473-3099(21)00648-4

Citation Report

#	Article	IF	CITATIONS
6	Covid-19: One in four vaccinated people living in households with a covid-19 case become infected, study finds. BMJ, The, 2021, 375, n2638.	6.0	1
7	What is the vaccine effect on reducing transmission in the context of the SARS-CoV-2 delta variant?. Lancet Infectious Diseases, The, 2022, 22, 152-153.	9.1	46
9	Multistate Outbreak of SARS-CoV-2 Infections, Including Vaccine Breakthrough Infections, Associated with Large Public Gatherings, United States. Emerging Infectious Diseases, 2022, 28, 36-44.	4.3	19
11	Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters. Journal of Virology, 2022, 96, JVI0197321.	3.4	35
15	Diagnostic Performance of Automated SARS-CoV-2 Antigen Assay in Nasal Swab during COVID-19 Vaccination Campaign. Diagnostics, 2021, 11, 2110.	2.6	6
18	Household Transmission of SARS-CoV-2: A Prospective Longitudinal Study Showing Higher Viral Load and Increased Transmissibility of the Alpha Variant Compared to Previous Strains. Microorganisms, 2021, 9, 2371.	3.6	26
20	Broadening symptom criteria improves early case identification in SARS-CoV-2 contacts. European Respiratory Journal, 2022, 60, 2102308.	6.7	7
21	Clinical Phenotype and Contagiousness of Early Breakthrough SARS-CoV-2 Infections after BNT162b2 COVID-19 mRNA Vaccine: A Parallel Cohort Study in Healthcare Workers. Vaccines, 2021, 9, 1377.	4.4	6
24	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet, The, 2021, 398, 2258-2276.	13.7	519
25	The epidemiological relevance of the COVID-19-vaccinated population is increasing. Lancet Regional Health - Europe, The, 2021, 11, 100272.	5.6	24
27	Impact of time elapsed since full vaccination on SARS-CoV-2 RNA load in Delta-variant breakthrough COVID-19. Journal of Infection, 2022, 84, 579-613.	3.3	5
28	A, B, C, or D? Reader Says â€~None of the Above' on Question of Breakthrough COVID Cases. ASA Monitor, 2022, 86, e2-e2.	0.1	O
30	Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence. Viruses, 2022, 14, 187.	3.3	66
31	Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. Nature Communications, 2022, 13, 532.	12.8	53
33	Mesenchymal Stem Cell-Based COVID-19 Therapy: Bioengineering Perspectives. Cells, 2022, 11, 465.	4.1	3
34	Longitudinal waning of mRNA vaccine-induced neutralizing antibodies against SARS-CoV-2 detected by an LFIA rapid test. Antibody Therapeutics, 2022, 5, 55-62.	1.9	6
37	Lung Function After Coronavirus Disease 2019: Some Answers, More Questions. Journal of Infectious Diseases, 2022, , .	4.0	0
40	COVID-19 vaccine strategies must focus on severe disease and global equity. Lancet, The, 2022, 399, 406-410.	13.7	55

#	ARTICLE	IF	CITATIONS
41	Transmissibility of SARS-CoV-2 among fully vaccinated individuals. Lancet Infectious Diseases, The, 2022, 22, 16-17.	9.1	5
42	Transmissibility of SARS-CoV-2 among fully vaccinated individuals – Authors' reply. Lancet Infectious Diseases, The, 2022, 22, 18-19.	9.1	3
43	Echinacea as a Potential Force against Coronavirus Infections? A Mini-Review of Randomized Controlled Trials in Adults and Children. Microorganisms, 2022, 10, 211.	3.6	14
44	The Burden of COVID-19 in Children and Its Prevention by Vaccination: A Joint Statement of the Israeli Pediatric Association and the Israeli Society for Pediatric Infectious Diseases. Vaccines, 2022, 10, 81.	4.4	26
46	Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models. EBioMedicine, 2022, 75, 103762.	6.1	32
47	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. Frontiers in Medicine, 2021, 8, 836826.	2.6	15
48	Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants. New England Journal of Medicine, 2022, 386, 744-756.	27.0	323
49	Reducing the rates of household transmission: The impact of COVID-19 vaccination in healthcare workers with a known household exposure. Vaccine, 2022, 40, 1213-1214.	3.8	4
51	Transmissibility of SARS-CoV-2 among fully vaccinated individuals. Lancet Infectious Diseases, The, 2022, 22, 16.	9.1	32
52	Transmissibility of SARS-CoV-2 among fully vaccinated individuals. Lancet Infectious Diseases, The, 2022, 22, 17-18.	9.1	1
53	Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel. Science, 2022, 375, 1151-1154.	12.6	109
54	SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant. Infectious Disease Clinics of North America, 2022, 36, 267-293.	5.1	10
56	School and community reopening during the COVID-19 pandemic: a mathematical modelling study. Royal Society Open Science, 2022, 9, 211883.	2.4	15
57	Genomic, immunological, and clinical analysis of COVIDâ€19 vaccine breakthrough infections in Beijing, China. Journal of Medical Virology, 2022, 94, 2237-2249.	5.0	13
59	Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine. Biomedicine and Pharmacotherapy, 2022, 147, 112650.	5.6	30
60	Comparative Analysis of Mortality From Coronavirus Disease 2019 Across the European Union Countries and the Effects of Vaccine Coverage. Open Forum Infectious Diseases, 2022, 9, ofac006.	0.9	4
62	Detoxifying the Fear of Epigenetic Changes Due to COVID Vaccination. American Journal of Medicine, 2022, , .	1.5	0
63	Comparison of the Anti-SARS-CoV-2 Surrogate Neutralization Assays by TECOmedical and DiaPROPH-Med with Samples from Vaccinated and Infected Individuals. Viruses, 2022, 14, 315.	3.3	8

3

#	ARTICLE	IF	CITATIONS
64	Longâ€ŧerm immunity in convalescent Syrian hamsters provides protection against newâ€variant SARSâ€CoVâ€2 infection of the lower but not upper respiratory tract. Journal of Medical Virology, 2022, 94, 2833-2836.	5.0	9
66	Drug repurposing for identification of potential spike inhibitors for SARS-CoV-2 using molecular docking and molecular dynamics simulations. Methods, 2022, 203, 498-510.	3.8	16
67	Influence of the Delta Variant and Vaccination on the SARS-CoV-2 Viral Load. Viruses, 2022, 14, 323.	3.3	13
68	Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak. Cell, 2022, 185, 485-492.e10.	28.9	38
69	Lack of Convincing Evidence that the Widely Used COVID-19 Vaccines will Produce Herd Immunity. American Journal of Medicine, 2022, , .	1.5	0
70	The Effects of Climate and Bioclimate on COVID-19 Cases in Poland. Remote Sensing, 2021, 13, 4946.	4.0	7
71	Neutralizing Response Against SARS-CoV-2 Variants 8 Months After BNT162b2 Vaccination in Naive and COVID-19–Convalescent Individuals. Journal of Infectious Diseases, 2022, 225, 1905-1908.	4.0	14
74	Can a combination of vaccination and face mask wearing contain the COVIDâ€19 pandemic?. Microbial Biotechnology, 2022, 15, 721-737.	4.2	41
75	Optimization of vaccination for COVID-19 in the midst of a pandemic. Networks and Heterogeneous Media, 2022, 17, 443.	1.1	7
76	Infectivity of Coronavirus Disease 2019: A Prospective Cohort Study in the Korean Metropolitan Area. Journal of Korean Medical Science, 2022, 37, e106.	2.5	3
77	Strengthening Community Defenses to Prevent and Control the Spread of COVID-19 in China. China CDC Weekly, 2022, 4, 191-194.	2.3	1
78	Two waves of COIVD-19 in Brazilian cities and vaccination impact. Mathematical Biosciences and Engineering, 2022, 19, 4657-4671.	1.9	8
79	Model-Estimated Association Between Simulated US Elementary School–Related SARS-CoV-2 Transmission, Mitigation Interventions, and Vaccine Coverage Across Local Incidence Levels. JAMA Network Open, 2022, 5, e2147827.	5.9	12
80	Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review. International Journal of Molecular Sciences, 2022, 23, 1987.	4.1	48
81	SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic. Frontiers of Medicine, 2022, 16, 185-195.	3.4	11
83	Rethinking routine airline testing during COVID-19. Nature Human Behaviour, 2022, 6, 310-310.	12.0	1
84	SARS-CoV-2 antigen lateral flow tests for detecting infectious people: linked data analysis. BMJ, The, 2022, 376, e066871.	6.0	14
86	Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic Symptoms. Open Forum Infectious Diseases, 2022, 9, ofac066.	0.9	17

#	Article	IF	CITATIONS
87	SARS-CoV-2 Delta Variant (AY.3) in the Feces of a Domestic Cat. Viruses, 2022, 14, 421.	3.3	15
88	Asymptomatic and pre-symptomatic infection in Coronavirus Disease 2019 pandemic. Medical Review, 2022, 2, 66-88.	1.2	12
89	Levels, Predictors, and Distribution of Interpersonal Solidarity during the COVID-19 Pandemic. International Journal of Environmental Research and Public Health, 2022, 19, 2041.	2.6	5
90	Lamarck redux and other false arguments against SARSâ€CoVâ€2 vaccination. EMBO Reports, 2022, 23, e54675.	4.5	2
91	Modeling Vaccine Efficacy for COVID-19 Outbreak in New York City. Biology, 2022, 11, 345.	2.8	15
92	An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission. Npj Vaccines, 2022, 7, 24.	6.0	18
93	Ivermectin for the prevention of COVID-19: addressing potential bias and medical fraud. Journal of Antimicrobial Chemotherapy, 2022, 77, 1413-1416.	3.0	10
94	Seroprevalence, Waning and Correlates of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of 35,193 Blood Donors Conducted between June 2020 and September 2021. Viruses, 2022, 14, 568.	3.3	17
95	Mumps to COVID-19: Vaccinated persons remain vulnerable when community uptake is low. Vaccine, 2022, 40, 1691-1694.	3.8	2
96	Assessing the Transmissibility of the New SARS-CoV-2 Variants: From Delta to Omicron. Vaccines, 2022, 10, 496.	4.4	9
97	Determining the reliability of rapid SARS-CoV-2 antigen detection in fully vaccinated individuals. Journal of Clinical Virology, 2022, 148, 105119.	3.1	10
98	BNT162b2 Vaccineâ€Associated Myo/Pericarditis in Adolescents: A Stratified Riskâ€Benefit Analysis. European Journal of Clinical Investigation, 2022, 52, e13759.	3.4	31
99	SARS-CoV-2 Transmission Risk Model in an Urban Area of Mexico, Based on GIS Analysis and Viral Load. International Journal of Environmental Research and Public Health, 2022, 19, 3840.	2.6	2
100	Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nature Medicine, 2022, 28, 1031-1041.	30.7	281
101	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. Open Forum Infectious Diseases, 2022, 9, ofac124.	0.9	25
103	Choice of SARS-CoV-2 diagnostic test: challenges and key considerations for the future. Critical Reviews in Clinical Laboratory Sciences, 2022, 59, 445-459.	6.1	17
104	COVID-19 symptoms are reduced by targeted hydration of the nose, larynx and trachea. Scientific Reports, 2022, 12, 4599.	3.3	15
108	Duration of infectious viral shedding in patients with mild to moderate COVID-19 treated with REGN-CoV2. Journal of Infection and Chemotherapy, 2022, , .	1.7	1

#	Article	IF	CITATIONS
109	The indirect effect of mRNA-based COVID-19 vaccination on healthcare workers' unvaccinated household members. Nature Communications, 2022, 13, 1162.	12.8	33
111	The genomic and clinical features of the COVID-19 Omicron variant: a narrative review. F1000Research, 0, 11, 353.	1.6	1
113	Local Surveillance of the COVID-19 Outbreak. Frontiers in Physics, 2022, 10, .	2.1	0
114	Functional analysis of polymorphisms at the S1/S2 site of SARS-CoV-2 spike protein. PLoS ONE, 2022, 17, e0265453.	2.5	8
115	Replacing quarantine of COVID-19 contacts with periodic testing is also effective in mitigating the risk of transmission. Scientific Reports, 2022, 12, 3620.	3.3	6
116	Higher vaccination rates predict reduction in SARS-CoV-2 transmission across the United States. Infection, 2022, 50, 1255-1266.	4.7	6
117	Government lockdown and mental health outcomes in the general population. The Cochrane Library, 2022, 2022, .	2.8	0
121	SARSâ€CoVâ€2 variants and vulnerability at the global level. Journal of Medical Virology, 2022, 94, 2986-3005.	5.0	79
122	Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. Nature Medicine, 2022, 28, 1491-1500.	30.7	239
123	A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model. Vaccine, 2022, 40, 2848-2855.	3.8	7
124	First Detection of SARS-CoV-2 B.1.617.2 (Delta) Variant of Concern in a Symptomatic Cat in Spain. Frontiers in Veterinary Science, 2022, 9, 841430.	2.2	16
125	Early Emergence Phase of SARS-CoV-2 Delta Variant in Florida, US. Viruses, 2022, 14, 766.	3.3	1
126	The Significance of Angling in Stress Reduction during the COVID-19 Pandemicâ€"Environmental and Socio-Economic Implications. International Journal of Environmental Research and Public Health, 2022, 19, 4346.	2.6	4
127	Prolonged viral shedding in severely ill patients infected with SARS-CoV-2 Delta variants: A retrospective cohort study. Journal of Infection, 2022, 85, 90-122.	3.3	1
128	Clinical and Virological Characteristics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) B.1.617.2 (Delta) Variant: A Prospective Cohort Study. Clinical Infectious Diseases, 2022, 75, e27-e34.	5.8	20
129	Variantâ€specific SARSâ€CoVâ€2 withinâ€host kinetics. Journal of Medical Virology, 2022, 94, 3625-3633.	5.0	11
130	Identification, propagation and molecular characterization of SARS-CoV-2 delta variant isolated from Egyptian COVID-19 patients. Infection, Genetics and Evolution, 2022, 100, 105278.	2.3	2
131	Temporal changes in factors associated with COVID-19 vaccine hesitancy and uptake among adults in Hong Kong: Serial cross-sectional surveys. The Lancet Regional Health - Western Pacific, 2022, 23, 100441.	2.9	100

#	ARTICLE	IF	CITATIONS
134	Anatomical Site, Viral Ribonucleic Acid Abundance, and Time of Sampling Correlate With Molecular Detection of Severe Acute Respiratory Syndrome Coronavirus 2 During Infection. Open Forum Infectious Diseases, 2022, 9, ofab623.	0.9	0
135	Vaccinations, Mobility and COVID-19 Transmission. International Journal of Environmental Research and Public Health, 2022, 19, 97.	2.6	16
138	How can risk of COVID-19 transmission be minimised in domiciliary care for older people: development, parameterisation and initial results of a simple mathematical model. Epidemiology and Infection, 2022, 150, .	2.1	2
141	SARS-CoV-2 vaccine boosters: The time to act is now. PLoS Medicine, 2021, 18, e1003882.	8.4	4
144	Durham University students' experiences of asymptomatic COVID-19 testing: a qualitative study. BMJ Open, 2021, 11, e055644.	1.9	3
145	An Agreement of Antigen Tests on Oral Pharyngeal Swabs or Less Invasive Testing With Reverse Transcription Polymerase Chain Reaction for Detecting SARS-CoV-2 in Adults: Protocol for a Prospective Nationwide Observational Study. JMIR Research Protocols, 2022, 11, e35706.	1.0	2
148	Mandatory covid-19 vaccination for healthcare workers: vaccinated and unvaccinated people seem as likely to infect others. BMJ, The, 2021, 375, n3027.	6.0	1
149	Diagnostic, Prognostic, and Therapeutic Value of Droplet Digital PCR (ddPCR) in COVID-19 Patients: A Systematic Review. Journal of Clinical Medicine, 2021, 10, 5712.	2.4	20
152	Inter-domain communication in SARS-CoV-2 spike proteins controls protease-triggered cell entry. Cell Reports, 2022, 39, 110786.	6.4	37
153	Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Perspective for Emerging More Transmissible and Vaccine-Resistant Strains. Viruses, 2022, 14, 827.	3.3	14
154	COVIDâ€19 transmission among vaccinated laboratory workers during the second wave in eastern Uttar Pradesh,Âlndia. Journal of Medical Virology, 2022, 94, 3512-3514.	5.0	1
155	Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test. , 2022, $1$ , .		5
156	Predictors of SARS-CoV-2 IgG Spike Antibody Responses on Admission and Clinical Outcomes of COVID-19 Disease in Fully Vaccinated Inpatients: The CoVax Study. Journal of Personalized Medicine, 2022, 12, 640.	2.5	3
157	Cancer diagnosis in Catalonia (Spain) after two years of COVID-19 pandemic: an incomplete recovery. ESMO Open, 2022, 7, 100486.	4.5	11
158	Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021. Vaccine, 2022, 40, 3027-3037.	3.8	18
160	Rapid evolution of SARS-CoV-2 challenges human defenses. Scientific Reports, 2022, 12, 6457.	3.3	18
161	Rapid Diagnostic Testing for SARS-CoV-2. New England Journal of Medicine, 2022, 386, e47.	27.0	3
162	COVID-19 Vaccine Hesitancy and Determinants of Acceptance among Healthcare Workers, Academics and Tertiary Students in Nigeria. Vaccines, 2022, 10, 626.	4.4	26

#	Article	IF	Citations
163	Differences in Transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) Variants. Microbiology Spectrum, 2022, 10, e0000822.	3.0	17
164	Evaluating the effects of second-dose vaccine-delay policies in European countries: A simulation study based on data from Greece. PLoS ONE, 2022, 17, e0263977.	2.5	5
165	Determinants of SARS-CoV-2 Contagiousness in Household Contacts of Symptomatic Adult Index Cases. Frontiers in Microbiology, 2022, 13, 829393.	3.5	9
166	SARS-CoV-2: Evolution and Emergence of New Viral Variants. Viruses, 2022, 14, 653.	3.3	39
167	Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants. Frontiers in Immunology, 2022, 13, 804945.	4.8	12
168	Delta Variant of SARS-CoV-2 Replacement in Brazil: A National Epidemiologic Surveillance Program. Viruses, 2022, 14, 847.	3.3	11
169	Dynamics of a Stochastic Epidemic Model with Vaccination and Multiple Time-Delays for COVID-19 in the UAE. Complexity, 2022, 2022, 1-15.	1.6	25
170	RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge. Translational Research, 2022, 248, 11-21.	5.0	13
171	Effectiveness of Messenger RNA–based Vaccines During the Emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant. Clinical Infectious Diseases, 2022, 75, 2186-2192.	5.8	12
172	Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell, 2022, 185, 2265-2278.e14.	28.9	77
173	Exploring the Utility of NK Cells in COVID-19. Biomedicines, 2022, 10, 1002.	3.2	12
174	Comparison of Home Antigen Testing With RT-PCR and Viral Culture During the Course of SARS-CoV-2 Infection. JAMA Internal Medicine, 2022, 182, 701.	5.1	80
175	Vaccination Is Reasonably Effective in Limiting the Spread of COVID-19 Infections, Hospitalizations and Deaths with COVID-19. Vaccines, 2022, 10, 678.	4.4	4
176	Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions. Human Vaccines and Immunotherapeutics, 2022, 18, 2068883.	3.3	44
177	Fear of COVID-19 predicts vaccination willingness 14 months later. Journal of Anxiety Disorders, 2022, 88, 102574.	3.2	32
178	Amplifying Appeals to the Common Good in COVID-19 Vaccine Messaging. JAMA Health Forum, 2022, 3, e220991.	2.2	0
179	Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques. Molecular Therapy, 2022, 30, 2952-2967.	8.2	2
180	SARS-CoV-2 Virus Dynamics in Recently Infected Peopleâ€"Data From a Household Transmission Study. Journal of Infectious Diseases, 2022, 226, 1699-1703.	4.0	2

#	Article	IF	CITATIONS
181	Active viral shedding in a vaccinated hospitalized patient infected with the delta variant (B.1.617.2) of SARS-CoV-2 and challenges of de-isolation. Journal of Infection and Public Health, 2022, 15, 628-630.	4.1	3
182	Breakthrough COVID-19 Infections in the US: Implications for Prolonging the Pandemic. Vaccines, 2022, 10, 755.	4.4	13
183	Breakthrough SARS-CoV-2 infections in double and triple vaccinated adults and single dose vaccine effectiveness among children in Autumn 2021 in England: REACT-1 study. EClinicalMedicine, 2022, 48, 101419.	7.1	8
184	A machine learning-based approach to determine infection status in recipients of BBV152 (Covaxin) whole-virion inactivated SARS-CoV-2 vaccine for serological surveys. Computers in Biology and Medicine, 2022, 146, 105419.	7.0	8
185	Household Secondary Attack Rates of SARS-CoV-2 by Variant and Vaccination Status. JAMA Network Open, 2022, 5, e229317.	5.9	145
187	Appropriate relaxation of non-pharmaceutical interventions minimizes the risk of a resurgence in SARS-CoV-2 infections in spite of the Delta variant. PLoS Computational Biology, 2022, 18, e1010054.	3.2	3
188	A Single Dose of BNT162b2 Messenger RNA Vaccine Induces Airway Immunity in Severe Acute Respiratory Syndrome Coronavirus 2 Naive and Recovered Coronavirus Disease 2019 Subjects. Clinical Infectious Diseases, 2022, 75, 2053-2059.	5.8	7
189	Clinical manifestations of COVIDâ€19 breakthrough infections: A systematic review and metaâ€analysis. Journal of Medical Virology, 2022, 94, 4234-4245.	5.0	14
190	Clinical Characteristics and Risk Factors for Mortality in Critical Coronavirus Disease 2019 Patients 50 Years of Age or Younger During the Delta Wave: Comparison With Patients > 50 Years in Korea. Journal of Korean Medical Science, 2022, 37, .	2.5	9
191	The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good. BMJ Global Health, 2022, 7, e008684.	4.7	122
192	Similar Duration of Viral Shedding of the Delta Variant of SARS-CoV-2 Between Vaccinated and Incompletely Vaccinated Individuals. Infection Control and Hospital Epidemiology, 0, , 1-13.	1.8	7
193	Theoretically quantifying the direct and indirect benefits of vaccination against SARS-CoV-2 in terms of avoided deaths. Scientific Reports, 2022, 12, .	3.3	1
194	Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals. JAMA Network Open, 2022, 5, e2213606.	5.9	65
195	The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants. Immunity, 2022, 55, 1316-1326.e4.	14.3	38
196	A Primer on <scp>Postâ€COVID</scp> â€19 Conditions and Implications for Clinical Pharmacists. JACCP Journal of the American College of Clinical Pharmacy, 0, , .	1.0	0
197	Leveraging South African <scp>HIV</scp> research to define <scp>SARSâ€CoV</scp> â€2 immunity triggered by sequential variants of concern. Immunological Reviews, 2022, 310, 61-75.	6.0	6
199	Vaccine mandates for healthcare workers beyond COVID-19. Journal of Medical Ethics, 2023, 49, 211-220.	1.8	18
201	SARS CoV-2 (Delta Variant) Infection Kinetics and Immunopathogenesis in Domestic Cats. Viruses, 2022, 14, 1207.	3.3	5

#	Article	IF	CITATIONS
202	Long Term Vaccination Strategies to Mitigate the Global Impact of SARS-CoV-2 Transmission: A Modelling Study. SSRN Electronic Journal, 0, , .	0.4	2
204	Mucosal Immune Response after the Booster Dose of the <i>BNT162b2</i> COVID-19 Vaccine. SSRN Electronic Journal, 0, , .	0.4	0
205	Significant Increase in Antibody Titers after the 3rd Booster Dose of the Pfizer–BioNTech mRNA COVID-19 Vaccine in Healthcare Workers in Greece. Vaccines, 2022, 10, 876.	4.4	16
206	Antibody Level Predicts the Clinical Course of Breakthrough Infection of COVID-19 Caused by Delta and Omicron Variants: A Prospective Cross-Sectional Study. Open Forum Infectious Diseases, 2022, 9, .	0.9	22
207	Allosteric Binders of ACE2 Are Promising Anti-SARS-CoV-2 Agents. ACS Pharmacology and Translational Science, 2022, 5, 468-478.	4.9	3
208	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. Vaccines, 2022, 10, 919.	4.4	23
210	Impact of rhinovirus on hospitalization during the COVID-19 pandemic: A prospective cohort study Journal of Clinical Virology, 2022, 156, 105197.	3.1	3
211	A population framework for predicting the proportion of people infected by the far-field airborne transmission of SARS-CoV-2 indoors. Building and Environment, 2022, , 109309.	6.9	5
212	Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine. Vaccine, 2022, 40, 4538-4543.	3.8	16
214	Unravelling the relationship between trust in government and voluntary adoption of preventative behaviour through health belief model: a cross-culture study. Kybernetes, 2022, ahead-of-print, .	2.2	5
215	COVID-19 differentiated measures for unvaccinated individuals: The need for clear goals and strong justifications. Vaccine, 2022, 40, 5333-5337.	3.8	5
217	Clinical evaluation of the Diagnostic Analyzer for Selective Hybridization (DASH): A point-of-care PCR test for rapid detection of SARS-CoV-2 infection. PLoS ONE, 2022, 17, e0270060.	2.5	2
218	Transmission of B.1.617.2 Delta variant between vaccinated healthcare workers. Scientific Reports, 2022, 12, .	3.3	9
219	Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	16
221	Considerations regarding Interpretation of Positive SARS-CoV-2 Molecular Results with Late Cycle Threshold Values. Journal of Clinical Microbiology, 2022, 60, .	3.9	4
222	Comparison of outward transmission potential between vaccinated and partially vaccinated or unvaccinated individuals with the SARS-CoV-2 delta variant infection. Journal of Infection, 2022, 85, e69-e71.	3.3	5
223	A nationwide analytical and clinical evaluation of 44 rapid antigen tests for SARS-CoV-2 compared to RT-qPCR. Journal of Clinical Virology, 2022, 153, 105214.	3.1	5
224	Polymer formulated self-amplifying RNA vaccine is partially protective against influenza virus infection in ferrets. Oxford Open Immunology, 2022, 3, .	2.8	2

#	Article	IF	CITATIONS
225	Horny for COVID. Extrapolation, 2022, 63, 55-73.	0.2	O
226	Adaptation and Validation of the Malay Version of the Stress and Anxiety to Viral Epidemics-6 Items Scale Among the General Population. Frontiers in Psychiatry, 0, 13, .	2.6	0
227	Prevalence of antibodies against SARS oVâ€⊋ in the Norwegian population, August 2021. Influenza and Other Respiratory Viruses, 2022, 16, 1004-1013.	3.4	7
228	Weekly Nowcasting of New COVID-19 Cases Using Past Viral Load Measurements. Viruses, 2022, 14, 1414.	3.3	5
229	Effect of vaccination on household transmission of SARS-CoV-2 Delta variant of concern. Nature Communications, 2022, $13$ , .	12.8	28
230	The Impact of Childhood and Parental Vaccination on SARS-CoV-2 Infection Rates in Children. Pediatric Infectious Disease Journal, 2022, 41, 841-845.	2.0	7
231	Urban monitoring, evaluation and application of COVID-19 listed vaccine effectiveness: a health code blockchain study. BMJ Open, 2022, 12, e057281.	1.9	1
233	The Mutational Landscape of SARS-CoV-2 Variants of Concern Recovered From Egyptian Patients in 2021. Frontiers in Microbiology, 0, $13$ , .	3.5	1
234	Vaccination and variants: Retrospective model for the evolution of Covid-19 in Italy. PLoS ONE, 2022, 17, e0265159.	2.5	4
235	Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. Annals of Internal Medicine, 2022, 175, 1258-1265.	3.9	63
236	COVID-19: Challenges of Viral Variants. Annual Review of Medicine, 2023, 74, 31-53.	12.2	43
237	Is the Harm-to-Benefit Ratio a Key Criterion in Vaccine Approval?. Frontiers in Medicine, 0, 9, .	2.6	3
238	Transplanting COVID-19 positive donors: Expanding our experience to widen the donor pool. Journal of Heart and Lung Transplantation, 2022, 41, 1382-1384.	0.6	2
240	Debulking different Corona (SARS-CoV-2 delta, omicron, OC43) and Influenza (H1N1, H3N2) virus strains by plant viral trap proteins in chewing gums to decrease infection and transmission. Biomaterials, 2022, 288, 121671.	11.4	16
241	Household Transmission of SARS-CoV-2 in Bhutan. BioMed Research International, 2022, 2022, 1-10.	1.9	0
242	Lack of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) transmission from a healthcare worker to a cohort of immunosuppressed patients during the SARS-CoV-2 omicron variant surge, California, 2022. Infection Control and Hospital Epidemiology, 0, , 1-2.	1.8	1
243	Magnitude and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Household Transmission: A Longitudinal Cohort Study. Clinical Infectious Diseases, 2022, 75, S193-S204.	5.8	9
245	Keeping up with the COVID'sâ€"Could siRNAâ€based antivirals be a part of the answer?. Exploration, 2022, 2, .	11.0	7

#	Article	IF	CITATIONS
246	Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission. Nature, 2022, 609, 101-108.	27.8	200
247	HDL cholesterol levels and susceptibility to COVID-19. EBioMedicine, 2022, 82, 104166.	6.1	11
248	Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variants compared with Alpha variant in vaccinated individuals. Science Translational Medicine, 2023, 15, .	12.4	22
249	Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. Journal of Hepatology, 2022, 77, 1161-1197.	3.7	46
250	Vaccination status, favipiravir, and micronutrient supplementation roles in post-COVID symptoms: A longitudinal study. PLoS ONE, 2022, 17, e0271385.	2.5	6
251	COVID-19 Vaccine for Children: Vaccination Willingness of Parents and Its Associated Factors—A Network Analysis. Vaccines, 2022, 10, 1155.	4.4	7
252	Sensitivity of Reverse Transcription Polymerase Chain Reaction Tests for Severe Acute Respiratory Syndrome Coronavirus 2 Through Time. Journal of Infectious Diseases, 2022, 227, 9-17.	4.0	12
253	From HIV to COVID-19,ÂMolecular mechanisms of pathogens' trade-off and persistence in the community, potential targets for new drug development. Bulletin of the National Research Centre, 2022, 46, .	1.8	0
254	Viral Load Dynamics in SARS-CoV-2 Omicron Breakthrough Infections. Journal of Infectious Diseases, 2022, 226, 1721-1725.	4.0	1
255	The genomic and clinical features of the COVID-19 Omicron variant: a narrative review. F1000Research, 0, 11, 353.	1.6	0
256	High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020–2021. Frontiers in Medicine, 0, 9, .	2.6	6
258	Coronavirus Disease 2019 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States Before the Delta- and Omicron-Associated Surges: A Retrospective Cohort Study of Repeat Blood Donors. Journal of Infectious Diseases, 2022, 226, 1556-1561	4.0	3
259	Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study. Lancet Respiratory Medicine, the, 2022, 10, 1061-1073.	10.7	60
260	Perspective: The Emerging Omicron Variant, Children And School. Current Pediatric Reviews, 2022, 18, .	0.8	0
261	Viral load may impact the diagnostic performance of nasal swabs in nucleic acid amplification test and quantitative antigen test for SARS-CoV-2 detection. Journal of Infection and Chemotherapy, 2022, , .	1.7	5
262	Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines. Human Immunology, 2022, 83, 755-767.	2.4	10
263	Why do people consent to receiving SARS-CoV-2 vaccinations? A representative survey in Germany. BMJ Open, 2022, 12, e060555.	1.9	6
265	Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. Journal of Clinical Investigation, 2022, 132, .	8.2	76

#	Article	IF	Citations
267	Genomic Surveillance of SARS-CoV-2 in the Southern Province of Zambia: Detection and Characterization of Alpha, Beta, Delta, and Omicron Variants of Concern. Viruses, 2022, 14, 1865.	3.3	1
268	The Omicron Variant BA.1.1 Presents a Lower Pathogenicity than B.1 D614G and Delta Variants in a Feline Model of SARS-CoV-2 Infection. Journal of Virology, 2022, 96, .	3.4	35
269	The Muslim Gaze and the COVID-19 Syndemic. Religions, 2022, 13, 780.	0.6	4
270	SARS-CoV-2 infection in households with and without young children: Nationwide cohort study, Denmark, 27 February 2020 to 26 February 2021. Eurosurveillance, 2022, 27, .	7.0	4
272	Impact of Age and Symptom Development on SARS-CoV-2 Transmission in Households With Children—Maryland, New York, and Utah, August 2020–October 2021. Open Forum Infectious Diseases, 2022, 9, .	0.9	3
273	The unmitigated profile of COVID-19 infectiousness. ELife, 0, 11, .	6.0	11
275	Assessing the Clinical and Socioeconomic Burden of Respiratory Syncytial Virus in Children Aged Under 5 Years in Primary Care: Protocol for a Prospective Cohort Study in England and Report on the Adaptations of the Study to the COVID-19 Pandemic. JMIR Research Protocols, 2022, 11, e38026.	1.0	2
276	At what frequency of vaccination do the vaccinated potentially pose an equal risk to the unvaccinated for transmission of SARS-CoV-2 inside restaurants in New York City?. Wiener Klinische Wochenschrift, 0, , .	1.9	O
279	Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses. Vaccines, 2022, 10, 1237.	4.4	2
280	Exhaled breath SARS-CoV-2 shedding patterns across variants of concern. International Journal of Infectious Diseases, 2022, 123, 25-33.	3.3	4
281	Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages. Cell Discovery, 2022, 8, .	6.7	13
282	Surfactin Bacterial Antiviral Lipopeptide Blocks In Vitro Replication of SARS-CoV-2. Applied Microbiology, 2022, 2, 680-687.	1.6	7
283	The landscape of potential health benefits of carotenoids as natural supportive therapeutics in protecting against Coronavirus infection. Biomedicine and Pharmacotherapy, 2022, 154, 113625.	5 <b>.</b> 6	4
284	SARS-CoV-2 Secondary Attack Rates in Vaccinated and Unvaccinated Household Contacts during Replacement of Delta with Omicron Variant, Spain. Emerging Infectious Diseases, 2022, 28, 1999-2008.	4.3	12
285	Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK). Lancet Regional Health - Europe, The, 2022, 22, 100501.	5.6	9
286	Infectious Probability Analysis on COVID-19 Spreading With Wireless Edge Networks. IEEE Journal on Selected Areas in Communications, 2022, 40, 3239-3254.	14.0	4
287	SARS-CoV-2-NaÃ-ve Korean Children and Adolescents Hospitalized With COVID-19 in 2021. Journal of Korean Medical Science, 2022, 37, .	2.5	4
288	COVID-19 Vaccination Trends and Public Views and Responses in Japan. , 2022, , 67-81.		1

#	Article	IF	CITATIONS
289	Diagnostic Performance, Stability, and Usability of Self-Collected Combo Swabs and Saliva for Coronavirus Disease 2019 Diagnosis: A Case-Control Study. Infection and Chemotherapy, 2022, 54, 517.	2.3	0
290	The pandemic of the unvaccinated: a Covid-19 ethical dilemma. Heart and Lung: Journal of Acute and Critical Care, 2022, , .	1.6	1
291	Moralization and Mismoralization in Public Health. Medicine, Health Care and Philosophy, 2022, 25, 655-669.	1.8	9
292	The Role of Knowledge, Attitude, Confidence, and Sociodemographic Factors in COVID-19 Vaccination Adherence among Adolescents in Indonesia: A Nationwide Survey. Vaccines, 2022, 10, 1489.	4.4	7
293	Randomized, Double-Blind, Placebo-Controlled Trial of a Throat Spray with Selected Lactobacilli in COVID-19 Outpatients. Microbiology Spectrum, 2022, 10, .	3.0	18
295	RNA loads of severe acute respiratory syndrome coronavirus 2 in patients with breakthrough coronavirus disease 2019 caused by the Delta and Omicron variants. Clinical Microbiology and Infection, 2022, , .	6.0	0
296	Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial). International Journal of Infectious Diseases, 2022, 124, 190-198.	3.3	4
297	Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. Nature Communications, 2022, 13, .	12.8	18
298	Curing the pandemic of misinformation on COVID-19 mRNA vaccines through real evidence-based medicine - Part 2. Journal of Insulin Resistance, 2022, 5, .	1.3	0
299	Infectious viral shedding of SARS-CoV-2 Delta following vaccination: A longitudinal cohort study. PLoS Pathogens, 2022, 18, e1010802.	4.7	27
300	Time intervals in the care pathway to cancer diagnosis during the COVIDâ€19 pandemic: A large retrospective study from a highâ€volume center. International Journal of Cancer, 2023, 152, 384-395.	5.1	7
301	Determinants of COVID-19 Vaccine Hesitancy During the Pandemic: A Cross-Sectional Survey in the Canton of Vaud, Switzerland. International Journal of Public Health, 0, 67, .	2.3	3
302	Vaccination willingness in association with personality traits in patients with multiple sclerosis in the course of SARS-CoV-2 pandemic. Scientific Reports, 2022, 12, .	3.3	4
304	Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine. Journal of the Formosan Medical Association, 2023, 122, 121-131.	1.7	9
305	Understanding spatiotemporal symptom onset risk of Omicron BA.1, BA.2 and hamster-related Delta AY.127. Frontiers in Public Health, 0, $10$ , .	2.7	1
307	Does Influenza Vaccination Reduce the Risk of Contracting COVID-19?. Journal of Clinical Medicine, 2022, 11, 5297.	2.4	1
308	Comparison of epidemiological characteristics and transmissibility of different strains of COVID-19 based on the incidence data of all local outbreaks in China as of March 1, 2022. Frontiers in Public Health, 0, 10, .	2.7	1
309	Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model. PLoS Pathogens, 2022, 18, e1010807.	4.7	15

#	Article	IF	CITATIONS
310	Consideration of COVID-19 beyond the human-centred approach of prevention and control: the ONE-HEALTH perspective. Emerging Microbes and Infections, 2022, 11, 2520-2528.	6.5	6
311	Long-Term Antibody Response to SARS-CoV-2 in Children. Journal of Clinical Immunology, 2023, 43, 46-56.	3.8	8
312	A single-administration therapeutic interfering particle reduces SARS-CoV-2 viral shedding and pathogenesis in hamsters. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	5
313	Impact of COVIDâ€19 vaccination on transmission risk of breakthrough infections: Lessons from adapted N95 mask sampling for emerging variants and interventions. Journal of Medical Virology, 2023, 95, .	5.0	2
315	Assessing the mechanism of citywide test-trace-isolate Zero-COVID policy and exit strategy of COVID-19 pandemic. Infectious Diseases of Poverty, 2022, 11, .	3.7	10
316	Household transmission of the Delta COVID-19 variant in Queensland, Australia: a case series. Epidemiology and Infection, 2022, 150, .	2.1	5
317	SARS-CoV-2 nasopharyngeal viral load in individuals infected with BA.2, compared to Alpha, Gamma, Delta and BA.1 variants: A single-center comparative analysis. Journal of Clinical Virology, 2022, 157, 105299.	3.1	5
318	Impact of COVID-19 vaccination on public compliance with epidemiological measures and rules of public prevention. Sanitarnyj VraÄ <sub>§</sub> 2022, , 716-727.	0.5	0
319	Healthcare-Associated COVID-19 across Five Pandemic Waves: Prediction Models and Genomic Analyses. Viruses, 2022, 14, 2292.	3.3	1
320	The Rescue of the Romanian Health System by the Emergency Departments during the Fourth Wave of COVID-19 Pandemic. Life, 2022, 12, 1547.	2.4	1
321	Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. Vaccines, 2022, 10, 1751.	4.4	10
322	Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science, 2022, 378, .	12.6	141
323	Rates of Asymptomatic COVID-19 Infection and Associated Factors in Olmsted County, MN in the Pre-Vaccination Era. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2022, , .	2.4	0
324	Exploring the Role of Antiviral Nasal Sprays in the Control of Emerging Respiratory Infections in the Community. Infectious Diseases and Therapy, 2022, 11, 2287-2296.	4.0	7
325	Morning SARS-CoV-2 Testing Yields Better Detection of Infection Due to Higher Viral Loads in Saliva and Nasal Swabs upon Waking. Microbiology Spectrum, 2022, 10, .	3.0	7
326	A comprehensive update on CIDO: the community-based coronavirus infectious disease ontology. Journal of Biomedical Semantics, 2022, 13, .	1.6	7
327	Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates. Npj Vaccines, 2022, 7, .	6.0	4
328	Four points regarding reproducibility and external statistical validity. Journal of Evidence-Based Medicine, 2022, 15, 317-319.	1.8	1

#	Article	IF	CITATIONS
330	Contact tracing reveals community transmission of COVID-19 in New York City. Nature Communications, 2022, $13$ , .	12.8	8
331	The Impact of the COVID-19 Pandemic on Informal Caregivers of People With Parkinson's Disease Residing in the UK: A Qualitative Study. Journal of Geriatric Psychiatry and Neurology, 0, , 089198872211355.	2.3	6
332	Daily, self-test rapid antigen test to assess SARS-CoV-2 viability in de-isolation of patients with COVID-19. Frontiers in Medicine, $0, 9, .$	2.6	3
333	Modelling the impact of repeat asymptomatic testing policies for staff on SARS-CoV-2 transmission potential. Journal of Theoretical Biology, 2023, 557, 111335.	1.7	3
334	Household secondary attack rate in SARS-CoV-2 infection during the second wave of the COVID-19 pandemic in South India. Journal of Family Medicine and Primary Care, 2022, 11, 6268.	0.9	0
335	Evaluating methodological approaches to assess the severity of infection with SARS-CoV-2 variants: scoping review and applications on Belgian COVID-19 data. BMC Infectious Diseases, 2022, 22, .	2.9	5
337	A comparison of the protective effect of vaccination and clinical features between the SARS-CoV-2 wild-type strain and Delta (B.1.617.2) variant. Archives of Medical Science, 2022, 18, 1678-1682.	0.9	1
338	Effectiveness of SARSâ€CoVâ€2â€inactivated vaccine and the correlation to neutralizing antibodies: A testâ€negative case–control study. Journal of Medical Virology, 2023, 95, .	5.0	3
339	A Vaccine of SARS-CoV-2 S Protein RBD Induces Protective Immunity. International Journal of Molecular Sciences, 2022, 23, 13716.	4.1	3
340	Transmission of SARS-CoV-2 during indoor clubbing events: A clustered randomized, controlled, multicentre trial protocol. Frontiers in Public Health, 0, $10$ , .	2.7	1
341	Antigenic escape is accelerated by the presence of immunocompromised hosts. Proceedings of the Royal Society B: Biological Sciences, 2022, 289, .	2.6	3
342	Why Molnupiravir Fails in Hospitalized Patients. MBio, 2022, 13, .	4.1	4
344	The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far. Vaccines, 2022, 10, 1926.	4.4	29
346	COVID-19 Vaccines and the Virtues. Public Health Ethics, 0, , .	1.0	0
347	Persisting Vaccine Hesitancy in Africa: The Whys, Global Public Health Consequences and Ways-Out—COVID-19 Vaccination Acceptance Rates as Case-in-Point. Vaccines, 2022, 10, 1934.	4.4	16
348	Aerosol formation during processing of potentially infectious samples on Roche immunochemistry analyzers (cobas e analyzers) and in an end-to-end laboratory workflow to model SARS-CoV-2 infection risk for laboratory operators. Frontiers in Public Health, 0, 10, .	2.7	0
349	A review of COVID vaccines: success against a moving target. British Medical Bulletin, 2022, 144, 12-44.	6.9	5
350	Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: A retrospective cohort study. ELife, 0, $11$ , .	6.0	53

#	Article	IF	CITATIONS
351	Reactogenicity and Immunogenicity of the ChAdOx1 nCOV-19 Coronavirus Disease 2019 Vaccine in South Korean Healthcare Workers. Yonsei Medical Journal, $0, 63, \ldots$	2.2	5
352	Analysis of two choir outbreaks acting in concert to characterize long-range transmission risks through SARS-CoV-2, Berlin, Germany, 2020. PLoS ONE, 2022, 17, e0277699.	2.5	7
353	A four-generation family transmission chain of COVID-19 along the China–Myanmar border in October to November 2021. Frontiers in Public Health, 0, 10, .	2.7	3
354	Vaccine Effect on Household Transmission of Omicron and Delta SARS-CoV-2 Variants. Journal of Korean Medical Science, 2023, 38, .	2.5	4
355	Incidence of SARS-CoV-2 infection in hospital workers before and after vaccination programme in East Java, Indonesia – aÂretrospective cohort study. , 2023, 10, 100130.		5
356	Agent-based model of the impact of higher influenza vaccine efficacy on seasonal influenza burden. Vaccine: X, 2023, 13, 100249.	2.1	1
357	AN ANALYSIS OF THE LEGAL RAMIFICATIONS OF MANDATORY VACCINATION IN THE LIGHT OF RIGHTS TO LIFE AND HEALTH: THE CASE OF SRI LANKA. , $2022$ , , $117$ - $128$ .		0
358	Statistics in Times of Increasing Uncertainty. Journal of the Royal Statistical Society Series A: Statistics in Society, 2022, 185, 1471-1496.	1.1	1
359	Waning of Humoral Immunity and the Influencing Factors after BNT162b2 Vaccination: A Cohort Study with a Latent Growth Curve Model in Fukushima. Vaccines, 2022, 10, 2007.	4.4	3
360	Impact of Vaccination With the SCB-2019 Coronavirus Disease 2019 Vaccine on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Household Contact Study in the Philippines. Clinical Infectious Diseases, 2023, 76, 1180-1187.	5.8	3
361	Endemicity Is Not a Victory: The Unmitigated Downside Risks of Widespread SARS-CoV-2 Transmission. Covid, 2022, 2, 1689-1709.	1.5	3
362	Modeling the effect of temperature and relative humidity on exposure to <scp>SARS oV</scp> â€2 in a mechanically ventilated room. Indoor Air, 2022, 32, .	4.3	4
363	AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019. Clinical Infectious Diseases, 2023, 76, 1247-1256.	5.8	16
364	Mental health in the Austrian general population during COVID-19: Cross-sectional study on the association with sociodemographic factors. Frontiers in Psychiatry, $0,13,.$	2.6	13
365	A Comparison Study of the Detection Limit of Omicron SARS-CoV-2 Nucleocapsid by Various Rapid Antigen Tests. Biosensors, 2022, 12, 1083.	4.7	5
367	Omicron variant: assessing the duration of viral shedding and its implications. Clinical Microbiology and Infection, 2022, , .	6.0	0
368	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. Frontiers in Bioengineering and Biotechnology, 0, 10, .	4.1	3
370	COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities. Journal of Medical Ethics, 2024, 50, 126-138.	1.8	16

#	Article	IF	CITATIONS
371	Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice. Vaccines, 2023, 11, 30.	4.4	3
372	Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021. Vaccine, 2023, 41, 1808-1818.	3.8	3
373	Coupling the Within-Host Process and Between-Host Transmission of COVID-19 Suggests Vaccination and School Closures are Critical. Bulletin of Mathematical Biology, 2023, 85, .	1.9	3
374	SARS-CoV-2 viral load and shedding kinetics. Nature Reviews Microbiology, 0, , .	28.6	57
375	Do we need nasal vaccines against COVID 19 to suppress the transmission of infections?. Microbial Biotechnology, 2023, 16, 3-14.	4.2	6
376	Donor selection for adoptive cell therapy with CD45RAâ^' memory T cells for patients with coronavirus disease 2019, and dexamethasone and interleukin-15 effects on the phenotype, proliferation and interferon gamma release. Cytotherapy, 2023, 25, 330-340.	0.7	2
377	Prevalence and risk factors of Severe Acute Respiratory Syndrome Coronavirus 2 infection in women and children in peri-urban communities in Pakistan: A prospective cohort study. Journal of Global Health, 0, 12, .	2.7	0
378	An efficacy and safety report based on randomized controlled single-blinded multi-centre clinical trial of ZingiVir-H, a novel herbo-mineral formulation designed as an add-on therapy in adult patients with mild to moderate COVID-19. PLoS ONE, 2022, 17, e0276773.	2.5	0
379	SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBioMedicine, 2023, 87, 104402.	6.1	45
381	Altruistic Vaccination: Insights from Two Focus Group Studies. Health Care Analysis, 2022, 30, 275-295.	2.2	3
382	Association between COVID-19 Primary Vaccination and Severe Disease Caused by SARS-CoV-2 Delta Variant among Hospitalized Patients: A Belgian Retrospective Cohort Study. Vaccines, 2023, 11, 14.	4.4	1
383	The Ethical Significance of Post-Vaccination COVID-19 Transmission Dynamics. Journal of Bioethical Inquiry, 2023, 20, 21-29.	1.5	3
384	Effectiveness of covid-19 vaccines in adolescents and children. BMJ, The, 0, , o3018.	6.0	0
386	Vaccinated Healthcare Workers' Adherence to COVID-19 Prevention Measures and Associated Factors in Northwest Ethiopia: A Facility-Based Cross-Sectional Study. Risk Management and Healthcare Policy, 0, Volume 15, 2389-2398.	2.5	0
387	Socio-demographical Profile of 7285 SARS-Cov-2 Positive Early Cases; Comparison with National Four Epidemic Waves. Medical Journal of the Islamic Republic of Iran, 0, , .	0.9	0
388	Who is watching the World Health Organisation?  Post-truth' moments beyond infodemic research. The Journal for Transdisciplinary Research in Southern Africa, 2022, 18, .	0.5	О
389	Commentary on the impact of the COVID-19 passports in Lithuania. Journal of Infection, 2023, 86, e78-e79.	3.3	1
390	A fractional-order mathematical model based on vaccinated and infected compartments of SARS-CoV-2 with a real case study during the last stages of the epidemiological event. Journal of Computational and Applied Mathematics, 2023, 425, 115015.	2.0	6

#	Article	IF	CITATIONS
391	Contextualizing Wastewater-Based surveillance in the COVID-19 vaccination era. Environment International, 2023, 171, 107718.	10.0	5
392	Do you take off your mask correctly? A survey during COVID-19 pandemic in Ningbo, China. PLoS ONE, 2022, 17, e0279093.	2.5	0
393	Association Between Population-Level Factors and Household Secondary Attack Rate of SARS-CoV-2: A Systematic Review and Meta-analysis. Open Forum Infectious Diseases, 2023, 10, .	0.9	1
394	Evaluation of Interventions to Improve Ventilation in Households to Reduce Risk for Transmission of Severe Acute Respiratory Syndrome Coronavirus 2. Pathogens and Immunity, 2022, 7, 120-130.	3.1	2
395	Community risks for SARS-CoV-2 infection among fully vaccinated US adults by rurality: A retrospective cohort study from the National COVID Cohort Collaborative. PLoS ONE, 2023, 18, e0279968.	2.5	2
397	Oral booster vaccine antigen—Expression of fullâ€length native <scp>SARSâ€CoV</scp> â€2 spike protein in lettuce chloroplasts. Plant Biotechnology Journal, 2023, 21, 887-889.	8.3	2
398	Effects of Second Dose of SARS-CoV-2 Vaccination on Household Transmission, England. Emerging Infectious Diseases, 2023, 29, 127-132.	4.3	5
399	Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. Nature Medicine, 2023, 29, 358-365.	30.7	108
400	Predictors of COVID-19 vaccine hesitancy in Chad: A cross-sectional study. Frontiers in Public Health, 0, 10, .	2.7	4
402	A Millian Case for Censoring Vaccine Misinformation. Journal of Bioethical Inquiry, 0, , .	1.5	1
403	Willingness to receive COVID-19 vaccination and adverse effects after vaccination in breast cancer survivors during the COVID-19 pandemic: a cross-sectional retrospective study of a Chinese population. Annals of Translational Medicine, 2023, .	1.7	0
404	SARS-CoV-2 Infection in Captive Hippos (Hippopotamus amphibius), Belgium. Animals, 2023, 13, 316.	2.3	12
405	Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine. EBioMedicine, 2023, 88, 104435.	6.1	20
406	Other Facets of SARS-CoV-2 Immunity, the Risk of Immune Tolerance and T Cell Exhaustion. , 2023, , 325-363.		0
407	Environmental, biological and social factors contributing to new rises in COVID-19 morbidity in Russia. BIOpreparations Prevention Diagnosis Treatment, 2022, 22, 351-360.	0.5	1
408	Viral shedding patterns of symptomatic SARS-CoV-2 infections by periods of variant predominance and vaccination status in Gyeonggi Province, Korea. Epidemiology and Health, 0, 45, e2023008.	1.9	1
409	Prevalence of <scp>SARS oV</scp> â€2 infection among oral health care workers worldwide: A metaâ€analysis. Community Dentistry and Oral Epidemiology, 2023, 51, 718-728.	1.9	6
410	Hesitancy towards COVID-19 vaccination: The role of personality traits, anti-vaccine attitudes and illness perception. PLOS Global Public Health, 2022, 2, e0001435.	1.6	3

#	ARTICLE	IF	Citations
412	Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines. Trends in Molecular Medicine, 2023, 29, 255-267.	6.7	17
413	COVID-19 vaccination hesitancy among Italian parents: A systematic review and meta-analysis. Human Vaccines and Immunotherapeutics, 2023, 19, .	3.3	9
414	Association of Culturable-Virus Detection and Household Transmission of SARS-CoV-2, California and Tennessee, 2020–2022. Journal of Infectious Diseases, 2023, 227, 1343-1347.	4.0	1
415	Severe COVID-19 Infection during Pregnancy Requiring ECMO: Case Report and Review of the Literature. Journal of Personalized Medicine, 2023, 13, 263.	2.5	4
416	Quantification of Severe Acute Respiratory Syndrome Coronavirus 2 Binding Antibody Levels To Assess Infection and Vaccine-Induced Immunity Using WHO Standards. Microbiology Spectrum, 2023, 11, .	3.0	4
417	Evaluation of Vaccination Level and Vaccine Literacy in Vocational Health School Students. Acibadem Universitesi Saglik Bilimleri Dergisi, 2023, 14, .	0.1	0
418	Clustering of SARS-CoV-2 in Households in New York City: A Building-Level Analysis, March-December 2020. Journal of Public Health Management and Practice, O, Publish Ahead of Print, .	1.4	0
419	Oral Immunization with Escherichia coli Nissle 1917 Expressing SARS-CoV-2 Spike Protein Induces Mucosal and Systemic Antibody Responses in Mice. Biomolecules, 2023, 13, 569.	4.0	4
420	Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxximâ,,¢ elicits strong antibody and T-cell responses in mice. Scientific Reports, 2023, 13, .	3.3	5
421	Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021–2022. Vaccine, 2023, 41, 3292-3300.	3.8	12
422	Multiple cohort study of hospitalized SARS-CoV-2 in-host infection dynamics: Parameter estimates, identifiability, sensitivity and the eclipse phase profile. Journal of Theoretical Biology, 2023, 564, 111449.	1.7	6
423	Vaccines Alone Cannot Slow the Evolution of SARS-CoV-2. Vaccines, 2023, 11, 853.	4.4	4
424	Real-life lack of evidence of viable SARS-CoV-2 transmission via inanimate surfaces: The SURFACE study. Journal of Infection and Public Health, 2023, 16, 736-740.	4.1	2
425	Comparative assessment of efficacy and immunogenicity of Gam-COVID-Vac and CoviVac vaccines against SARS-CoV-2. Profilakticheskaya Meditsina, 2022, 25, 82.	0.6	1
426	SARS-CoV-2 infection dynamics and genomic surveillance to detect variants in wastewater – a longitudinal study in Bengaluru, India. , 2023, 11, 100151.		7
427	Effect of COVID-19 vaccination on the SARS-CoV-2 transmission among social and household close contacts: A cohort study. Journal of Infection and Public Health, 2023, 16, 410-417.	4.1	7
428	Effective Health Screening and Prompt Vaccination to Counter the Spread of COVID-19 and Minimize Its Adverse Effects. Signals and Communication Technology, 2023, , 231-256.	0.5	0
429	SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: implications for future vaccination strategies. European Journal of Epidemiology, 2023, 38, 237-242.	5.7	7

#	Article	IF	CITATIONS
430	Immune Response and Molecular Mechanisms of Cardiovascular Adverse Effects of Spike Proteins from SARS-CoV-2 and mRNA Vaccines. Biomedicines, 2023, 11, 451.	3.2	10
431	Association between SARS-CoV-2 Viral Load and Patient Symptoms and Clinical Outcomes Using Droplet Digital PCR. Viruses, 2023, 15, 446.	3.3	4
433	Knowledge, Attitude, and Practice towards COVID-19 among Patients Attending Phuentsholing Hospital, Bhutan: A Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2023, 20, 2942.	2.6	1
434	Effects of the vaccination against SARS-CoV-2 on infections and on hospitalizations in European countries. SN Business & Economics, 2023, 3, .	1.1	2
435	Impact of COVID-19 on Cardiovascular Disease. Viruses, 2023, 15, 508.	3.3	15
436	Limited effect of reducing pulmonary tuberculosis incidence amid mandatory facial masking for COVID-19. Respiratory Research, 2023, 24, .	3.6	3
437	Simulating potential outbreaks of Delta and Omicron variants based on contact-tracing data: A modelling study in Fujian Province, China. Infectious Disease Modelling, 2023, 8, 270-281.	1.9	1
438	Computational framework to understand the clinical stages of COVIDâ€19 and visualization of time course for various treatment strategies. Biotechnology and Bioengineering, 0, , .	3.3	1
439	Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission: a prospective cohort study in England. Wellcome Open Research, 0, 8, 96.	1.8	0
440	Identification of hub genes associated with osteoporosis development by comprehensive bioinformatics analysis. Frontiers in Genetics, 0, 14, .	2.3	2
443	Monitoring and immunogenicity of SARS-CoV-2 vaccination of laboratory rhesus monkeys (Macaca) Tj ETQq0 0 (	) rgBT /Ov	erlock 10 Tf 5
444	Comparative pharmacological efficacy of COVID-19 vaccines against the variants of concerns (VOCs) of SARS-CoV-2: Recent clinical Studies on Booster dose. Current Pharmaceutical Biotechnology, 2023, 24, .	1.6	0
445	SARS oVâ€2 in animals: susceptibility of animal species, risk for animal and public health, monitoring, prevention and control. EFSA Journal, 2023, 21, .	1.8	16
446	SARS-CoV-2 Spike-Mediated Entry and Its Regulation by Host Innate Immunity. Viruses, 2023, 15, 639.	3.3	1
447	Vaccination reduces viral load and accelerates viral clearance in SARS-CoV-2 Delta variant-infected patients. Annals of Medicine, 2023, 55, 419-427.	3.8	4
448	Immune damage mechanisms of COVID-19 and novel strategies in prevention and control of epidemic. Frontiers in Immunology, 0, $14$ , .	4.8	1
449	Impact of inactivated vaccines on decrease of viral RNA levels in individuals with the SARS-CoV-2 Omicron (BA.2) variant: A retrospective cohort study in Shanghai, China. Frontiers in Public Health, 0, 11, .	2.7	2
450	Cost-effectiveness analysis of vaccination against COVID-19 in China. Frontiers in Public Health, 0, 11, .	2.7	0

#	Article	IF	CITATIONS
451	The causal effect of physical activity intensity on COVID-19 susceptibility, hospitalization, and severity: Evidence from a mendelian randomization study. Frontiers in Physiology, 0, 14, .	2.8	3
452	Retrospective, Observational Studies for Estimating Vaccine Effects on the Secondary Attack Rate of SARS-CoV-2. American Journal of Epidemiology, 0, , .	3.4	1
454	Identification of Z-Tyr-Ala-CHN2, a Cathepsin L Inhibitor with Broad-Spectrum Cell-Specific Activity against Coronaviruses, including SARS-CoV-2. Microorganisms, 2023, 11, 717.	3.6	1
455	Indirect Dispersion of SARS-CoV-2 Live-Attenuated Vaccine and Its Contribution to Herd Immunity. Vaccines, 2023, 11, 655.	4.4	3
456	Relative role of border restrictions, case finding and contact tracing in controlling SARS-CoV-2 in the presence of undetected transmission: a mathematical modelling study. BMC Medicine, 2023, 21, .	5.5	4
457	Open Questions over the COVID-19 Pandemic. , 2023, 1, 210-220.		0
458	SARS-CoV-2 M <sup>pro</sup> Protease Variants of Concern Display Altered Viral Substrate and Cell Host Target Galectin-8 Processing but Retain Sensitivity toward Antivirals. ACS Central Science, 2023, 9, 696-708.	11.3	14
460	Using rapid antigen testing for early, safe return-to-work for healthcare personnel after SARS-CoV-2 infection in a healthcare system in Pakistan: A retrospective cross-sectional study. PLOS Global Public Health, 2023, 3, e0001746.	1.6	0
461	Molecular Characterization and Cluster Analysis of SARS-CoV-2 Viral Isolates in KahramanmaraÅŸ City, Turkey: The Delta VOC Wave within One Month. Viruses, 2023, 15, 802.	3.3	1
462	SARS-CoV-2 breakthrough infection induces rapid memory and de novo TÂcell responses. Immunity, 2023, 56, 879-892.e4.	14.3	40
463	Mathematical Modeling Evaluates How Vaccinations Affected the Course of COVID-19 Disease Progression. Vaccines, 2023, 11, 722.	4.4	3
464	An Oral Galectin Inhibitor in COVID-19—A Phase II Randomized Controlled Trial. Vaccines, 2023, 11, 731.	4.4	3
465	Salivary Antibody Responses to Two COVID-19 Vaccines following Different Vaccination Regimens. Vaccines, 2023, 11, 744.	4.4	1
466	Building-Level Detection Threshold of SARS-CoV-2 in Wastewater. Microbiology Spectrum, 2023, 11, .	3.0	8
467	The diffusion of COVID-19 across Italian provinces: a spatial dynamic panel data approach with common factors. Regional Studies, 2024, 58, 285-305.	4.4	2
469	TNFÎ $\pm$ aggravates detrimental effects of SARS-CoV-2 infection in the liver. Frontiers in Immunology, 0, 14, $\cdot$	4.8	3
470	Barriers affecting COVID‑19 vaccination in Phalombe District, Malawi: A qualitative study. South African Medical Journal, 0, , .	0.6	1
471	Risk factors and vectors for SARS-CoV-2 household transmission: a prospective, longitudinal cohort study. Lancet Microbe, The, 2023, 4, e397-e408.	7.3	18

#	Article	IF	CITATIONS
472	Border Control for Infectious Respiratory Disease Pandemics: A Modelling Study for H1N1 and Four Strains of SARS-CoV-2. Viruses, 2023, 15, 978.	3.3	1
473	Airborne virus shedding of the alpha, delta, omicron SARS oVâ€⊋ variants and influenza virus in hospitalized patients. Journal of Medical Virology, 2023, 95, .	5.0	1
474	Investigating the Current Status of SARS-CoV-2 Antibodies in Hospital Staff. Pathogens, 2023, 12, 688.	2.8	0
475	Immunization requirements in medical school accreditation standards. Vaccine, 2024, 42, 753-756.	3.8	0
476	Wastewater Genomic Surveillance Captures Early Detection of Omicron in Utah. Microbiology Spectrum, 2023, 11, .	3.0	3
477	COVID-19 Prevention Behaviours and Vaccine Acceptability, and Their Association with a Behaviour Change Campaign in Somalia: Analysis of a Longitudinal Cohort. Vaccines, 2023, 11, 972.	4.4	0
478	Vaccination, human mobility, and COVID-19 health outcomes: Empirical comparison before and during the outbreak of SARSâ€Cov-2 B.1.1.529 (Omicron) variant. Vaccine, 2023, 41, 5097-5112.	3.8	3
479	Herd immunity, vaccination and moral obligation. Journal of Medical Ethics, 2023, 49, 636-641.	1.8	0
480	Blaming the unvaccinated during the COVID-19 pandemic: the roles of political ideology and risk perceptions in the USA. Journal of Medical Ethics, 0, , jme-2022-108825.	1.8	2
481	Vaccine-induced protection against SARS-CoV-2 requires IFN- $\hat{l}^3$ -driven cellular immune response. Nature Communications, 2023, 14, .	12.8	4
482	Viral emissions into the air and environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human study. Lancet Microbe, The, 2023, 4, e579-e590.	7.3	23
483	Changes in COVID-19 vaccine hesitancy at different times among residents in Guangzhou, China. Frontiers in Public Health, 0, $11$ , .	2.7	4
484	Clinical Characteristics and Risk Factors for Mortality in Critical COVID-19 Patients Aged 50 Years or Younger During Omicron Wave in Korea: Comparison With Patients Older Than 50 Years of Age. Journal of Korean Medical Science, 2023, 38, .	2.5	1
485	Rise of the RNA machines – self-amplification in mRNA vaccine design. Trends in Biotechnology, 2023, 41, 1417-1429.	9.3	6
486	Effect of COVID-19 vaccination on household transmission of SARS-CoV-2 in the Omicron era: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study. International Journal of Infectious Diseases, 2023, 134, 200-206.	3.3	4
487	SARS-CoV-2 omicron RBD forms a weaker binding affinity to hACE2 compared to Delta RBD in <i>in-silico</i> studies. Journal of Biomolecular Structure and Dynamics, 0, , 1-10.	<b>3.</b> 5	0
488	Adaptive variations in SARS-CoV-2 spike proteins: effects on distinct virus-cell entry stages. MBio, 0, , .	4.1	1
489	Hydroxypropyl-Î <sup>2</sup> -Cyclodextrin Depletes Membrane Cholesterol and Inhibits SARS-CoV-2 Entry into HEK293T-ACEhi Cells. Pathogens, 2023, 12, 647.	2.8	2

#	Article	IF	CITATIONS
490	The role of children in transmission of SARS-CoV-2 variants of concern within households: an updated systematic review and meta-analysis, as at 30 June 2022. Eurosurveillance, 2023, 28, .	7.0	1
492	SARS-CoV-2 transmission dynamics in bars, restaurants, and nightclubs. Frontiers in Microbiology, 0, 14, .	3.5	0
494	Unambiguous Linkage Between the Vaccination Coverage and the Spread of COVID-19: Geostatistical Evidence from the Slovak LAU 1 Regions. Journal of Geovisualization and Spatial Analysis, 2023, 7, .	4.3	1
495	Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters. Communications Medicine, 2023, 3, .	4.2	1
496	COVID-19 in immunocompromised children: comparison of SARS-CoV-2 viral load dynamics between the first and third waves. Brazilian Journal of Microbiology, 0, , .	2.0	0
497	The dynamics of SARS-CoV-2 infection in unvaccinated and vaccinated populations in Mumbai, India, between 28 December 2020 and 30 August 2021. Archives of Virology, 2023, 168, .	2.1	0
498	Viral Load in of Patients Vaccinated with Various Vaccination Schemes. SN Comprehensive Clinical Medicine, 2023, 5, .	0.6	0
499	Severity and Vaccine Effectiveness in Patients With the Omicron Variant of COVID-19 in Suzhou: A Retrospective Single-Center Study. Cureus, 2023, , .	0.5	0
500	Bivalent mRNA vaccines against three SARS-CoV-2 variants mediated by new ionizable lipid nanoparticles. International Journal of Pharmaceutics, 2023, 642, 123155.	5.2	3
501	Humoral immune responses associated with control of SARS-CoV-2 breakthrough infections in a vaccinated US military population. EBioMedicine, 2023, 94, 104683.	6.1	4
502	A joint Bayesian hierarchical model for estimating SARS-CoV-2 genomic and subgenomic RNA viral dynamics and seroconversion. Biostatistics, 0, , .	1.5	0
503	Factors associated with the formation of SARS-CoV-2 case-clusters in Danish schools: a nationwide register-based observational study. Epidemiology and Infection, 0, , 1-25.	2.1	0
504	Assessing the evolution of SARS-CoV-2 lineages and the dynamic associations between nucleotide variations. Access Microbiology, 2023, 5, .	0.5	0
505	The differences in virus shedding time between the Delta variant and original SARS-CoV-2 infected patients. Frontiers in Public Health, 0, $11$ , .	2.7	1
507	Considerations for de-escalating universal masking in healthcare centers. Antimicrobial Stewardship & Healthcare Epidemiology, 2023, 3, .	0.5	1
508	Covid Vaccination Disputes in Czechia: Political Myth-Making and Boundary Work. Minerva, 0, , .	2.4	0
509	<scp>SARSâ€CoV</scp> â€2 viral dynamic modeling to inform model selection and timing and efficacy of antiviral therapy. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12, 1450-1460.	2.5	3
510	Evaluating the spread of Omicron COVID-19 variant in Spain. Future Generation Computer Systems, 2023, 149, 547-561.	7.5	1

#	Article	IF	CITATIONS
511	Vaccination, time lost from work, and COVID-19 infections: a Canadian healthcare worker retrospective cohort study. Frontiers in Public Health, $0,11,10$	2.7	0
512	Vaccine effectiveness in symptom and viral load mitigation in COVID-19 breakthrough infections in South Korea. PLoS ONE, 2023, 18, e0290154.	2.5	1
513	Tissue-Resident Memory T Cell: Ontogenetic Cellular Mechanism and Clinical Translation. Clinical and Experimental Immunology, $0, \ldots$	2.6	0
514	How are countries responding differently to COVID-19: a systematic review of guidelines on isolation measures. Frontiers in Public Health, 0, $11$ , .	2.7	2
515	Association between SARS-CoV-2 Symptoms, Ct Values, and Serological Response in Vaccinated and Unvaccinated Healthcare Personnel. journal of applied laboratory medicine, The, 2023, 8, 871-886.	1.3	2
516	Protection against Severe Illness versus Immunityâ€"Redefining Vaccine Effectiveness in the Aftermath of COVID-19. Microorganisms, 2023, 11, 1963.	3.6	3
517	Effect of SARS-CoV-2 prior infection and mRNA vaccination on contagiousness and susceptibility to infection. Nature Communications, 2023, 14, .	12.8	6
518	A Flexible Regression Modeling Approach Applied to Observational Laboratory Virological Data Suggests That SARS-CoV-2 Load in Upper Respiratory Tract Samples Changes with COVID-19 Epidemiology. Viruses, 2023, 15, 1988.	3.3	0
519	Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infection. Nature Immunology, 2023, 24, 1711-1724.	14.5	17
520	Viral kinetics of sequential SARS-CoV-2 infections. Nature Communications, 2023, 14, .	12.8	1
521	Estimating long-term vaccine effectiveness against SARS-CoV-2 variants: a model-based approach. Nature Communications, 2023, 14, .	12.8	2
522	A study to assess the impact of the cobas point-of-care RT-PCR assay (SARS-CoV-2 and Influenza A/B) on patient clinical management in the emergency department of the University of California at Davis Medical Center. Journal of Clinical Virology, 2023, 168, 105597.	3.1	1
523	SARS-CoV-2 variants of concern in children and adolescents with COVID-19: a systematic review. BMJ Open, 2023, 13, e072280.	1.9	0
524	On the determinants of anti-COVID restriction and anti-vaccine movements: the case of loApro in Italy. Scientific Reports, 2023, 13, .	3.3	2
525	A collaborative approach to improving representation in viral genomic surveillance. PLOS Global Public Health, 2023, 3, e0001935.	1.6	0
526	The COVID-19 pandemic in Greenland, epidemic features and impact of early strict measures, March 2020 to June 2022. Eurosurveillance, 2023, 28, .	7.0	1
527	Vaccination has more to offer than direct clinical benefit: FDA's vaccine licensure process ignores population health and social determinants of disease. American Journal of Epidemiology, 0, , .	3.4	0
529	Mandatory Vaccination Against COVID-19 in Europe: Public Health Versus †Saved by the Bell' Individual Autonomy. European Union and Its Neighbours in A Globalized World, 2023, , 283-303.	0.1	2

#	Article	IF	CITATIONS
530	COVID-19 Infection Rates in Vaccinated and Unvaccinated Inmates: A Retrospective Cohort Study. Cureus, 2023, , .	0.5	0
531	Traditional Herbal Medicines and Their Active Constituents in Combating SARS-CoV-2 Infection. , 2023, , 137-188.		0
532	A Scalar Approach to Vaccination Ethics. Journal of Ethics, 2024, 28, 145-169.	0.6	0
533	Can variants, reinfection, symptoms and test types affect COVID-19 diagnostic performance? A large-scale retrospective study of AG-RDTs during circulation of Delta and Omicron variants, Czechia, December 2021 to February 2022. Eurosurveillance, 2023, 28, .	7.0	0
535	IgG level of the third booster dose for mRNA of SARS-CoV-2 vaccines among Iraqi healthcare workers. Medicine (United States), 2023, 102, e35444.	1.0	0
536	Molecular diagnostic approaches for SARS-CoV-2 detection and pathophysiological consequences. Molecular Biology Reports, 0, , .	2.3	O
537	Assessing the effects of SARS-CoV-2 vaccination on the risk of household transmission during delta variant circulation: a population-based data linkage cohort study. The Lancet Regional Health - Western Pacific, 2024, 42, 100930.	2.9	0
538	Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants. Vaccine, 2023, 41, 7116-7128.	3.8	2
539	Determining the impact of vaccination on SARS-CoV-2 RT-PCR cycle threshold values and infectious viral titres. Access Microbiology, 2023, 5, .	0.5	0
540	Protection from infection and reinfection due to the Omicron BA.1 variant in care homes. Frontiers in Immunology, 0, 14, .	4.8	1
541	Causes and costs of global COVID-19 vaccine inequity. Seminars in Immunopathology, 0, , .	6.1	0
542	Real-world effectiveness of an intranasal spray A8G6 antibody cocktail in the post-exposure prophylaxis of COVID-19. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	1
543	Assessment of hybrid population immunity to SARS-CoV-2 following breakthrough infections of distinct SARS-CoV-2 variants by the detection of antibodies to nucleoprotein. Scientific Reports, 2023, 13, .	3.3	0
544	Isolation may select for earlier and higher peak viral load but shorter duration in SARS-CoV-2 evolution. Nature Communications, 2023, 14, .	12.8	0
545	Tracking the structure and sentiment of vaccination discussions on Mumsnet. Social Network Analysis and Mining, 2023, 13, .	2.8	0
546	Evaluation of CoronaVac and CoviShield Vaccines on SARS-CoV-2 Infection in Healthcare Workers in Salvador, Brazil. Covid, 2023, 3, 1639-1647.	1.5	0
547	Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission: a prospective cohort study in England. Wellcome Open Research, 0, 8, 96.	1.8	2
549	The impact of vaccination and SARS-CoV-2 variants on the virological response to SARS-CoV-2 infections during the Alpha, Delta, and Omicron waves in England. Journal of Infection, 2024, 88, 21-29.	3.3	1

#	Article	IF	CITATIONS
550	A COVIDâ€19 cluster analysis in an office: Assessing the longâ€range aerosol and fomite transmissions with infection control measures. Risk Analysis, 0, , .	2.7	0
551	ls Covid-19 "vaccine uptake―in postsecondary education a "problem� A critical policy inquiry. Health (United Kingdom), 0, , .	1.5	0
552	The relationship between anxiety and COVIDâ€19â€associated isolation and lifestyle changes in the university community as a result of the SARSâ€CoVâ€2 pandemic. , 0, , .		0
553	SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responses. EBioMedicine, 2023, 98, 104893.	6.1	0
554	Viral dynamics of the SARS-CoV-2 Omicron Variant in Paediatric Patients; A prospective cohort study. Clinical Infectious Diseases, 0, , .	5.8	0
555	An expanded RT-PCR melting temperature coding assay to rapidly identify all known SARS-CoV-2 variants and sub-variants of concern. Scientific Reports, 2023, 13, .	3.3	0
556	The Omicron Variant of SARS-CoV-2 Virus: the Ability to Cause Disease in Persons with Immunity against COVID-19. Journal of NBC Protection Corps, 2023, 6, 44-55.	0.3	0
558	How many is good enough? An analysis of serological follow-up after vaccination against SARS-CoV-2. Postepy Higieny I Medycyny Doswiadczalnej, 2023, 77, 143-153.	0.1	0
559	A regional genomic surveillance program is implemented to monitor the occurrence and emergence of SARS-CoV-2 variants in Yubei District, China. Virology Journal, 2024, 21, .	3.4	0
560	Elaboration and Analysis of SARS-CoV-2 Data in the Frame of Occupational Safety and Health Assessment in Sustainable Engineering Systems. Safety, 2024, 10, 6.	1.7	0
561	Seroincidence of SARS-CoV-2 infection prior to and during the rollout of vaccines in a community-based prospective cohort of U.S. adults. Scientific Reports, 2024, 14, .	3.3	0
562	Does COVID-19 Vaccination Protect Contact Persons? A Systematic Review. Hygiene, 2024, 4, 23-48.	1.7	0
563	The swab site of the upper airways influences the diagnostic sensitivity for the omicron variant of SARSâ€CoVâ€2. Journal of Medical Virology, 2024, 96, .	5.0	0
564	Differential pathogenic and molecular features in neurological infection of SARS oVâ€2 Omicron BA.5.2 and BA.2.75 and Delta. Journal of Medical Virology, 2024, 96, .	5.0	0
565	Protecting mass-gathering events in a pandemic with testing tracks and transparent information: an experimental study with festival guests. Psychology and Health, 0, , 1-27.	2,2	0
566	What makes SARSâ€CoVâ€2 unique? Focusing on the spike protein. Cell Biology International, 2024, 48, 404-430.	3.0	0
568	Association between COVID-19 Vaccination and SARS-CoV-2 Infection among Household Contacts of Infected Individuals: A Prospective Household Study in England. Vaccines, 2024, 12, 113.	4.4	0
569	The spike protein of the apathogenic Beaudette strain of avian coronavirus can elicit a protective immune response against a virulent M41 challenge. PLoS ONE, 2024, 19, e0297516.	2.5	0

#	ARTICLE	IF	Citations
570	Combined analyses of within-host SARS-CoV-2 viral kinetics and information on past exposures to the virus in a human cohort identifies intrinsic differences of Omicron and Delta variants. PLoS Biology, 2024, 22, e3002463.	5 <b>.</b> 6	2
572	Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults. Science Immunology, 2024, 9, .	11.9	2
573	Investigating the rise of Omicron variant through genomic surveillance of SARS-CoV-2 infections in a highly vaccinated university population. Microbial Genomics, 2024, 10, .	2.0	0
574	Genomic attributes of airway commensal bacteria and mucosa. Communications Biology, 2024, 7, .	4.4	0
575	Relationship between the Viral Load in Patients with Different COVID-19 Severities and SARS-CoV-2 Variants. Microorganisms, 2024, 12, 428.	3.6	0
576	Quantifying the relationship between within-host dynamics and transmission for viral diseases of livestock. Journal of the Royal Society Interface, 2024, 21, .	3.4	0
577	Nasopharyngeal angiotensin converting enzyme 2 (ACE2) expression as a risk-factor for SARS-CoV-2 transmission in concurrent hospital associated outbreaks. BMC Infectious Diseases, 2024, 24, .	2.9	0
578	Current state of COVID-19 in children: 4 years on. Journal of Infection, 2024, 88, 106134.	3.3	0
580	Association of Demographic, Clinical, and Vaccination Characteristics with COVID-19 Viral Load Assessed by qRT-PCR. Archives of Iranian Medicine, 2023, 26, 688-694.	0.6	0
581	Genomic Characterization of SARS-CoV-2 Variants from Clinical Isolates during the COVID-19 Epidemic in Mauritania. Genes, 2024, 15, 361.	2.4	0
582	COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history. PLoS ONE, 2024, 19, e0294897.	2.5	0
583	Characteristics of infections with ancestral, Beta and Delta variants of SARS-CoV-2 in the PHIRST-C community cohort study, South Africa, 2020-2021. BMC Infectious Diseases, 2024, 24, .	2.9	0
584	Detecting changes in generation and serial intervals under varying pathogen biology, contact patterns and outbreak response. PLoS Computational Biology, 2024, 20, e1011967.	3.2	0
585	Yeast-Based Screening of Anti-Viral Molecules. Microorganisms, 2024, 12, 578.	3.6	0